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A
 
BSTRACT
 
Early introduction of inhaled steroids as a treatment for
childhood asthma is recommended in the guidelines
to achieve not only early control of symptoms with an
improvement in patients’ quality of life, but also for the
inhibition of airway remodeling. The evidence suggest-
ing clinical usefulness of early intervention with inhaled
steroids exists in school-age or older children with
asthma. However, further investigations are required
to determine the value of early intervention with
inhaled steroids in asthmatic infants and very young
children, because the disease concept and diagnosis
of asthma, as well as clinical usefulness and adverse
reactions to inhaled steroids, have not been sufficiently
investigated.
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I
 
NTRODUCTION
 
The pathophysiology of bronchial asthma has been
investigated mainly for adult asthma. It has been eluci-
dated that asthma is a chronic inflammatory disorder
characterized by recurrent episodes of airway obstruc-
tion and hyperresponsiveness to various stimuli. It has
also been pointed out that airway remodeling occurs
due to sustained airway inflammation and this condition
makes the disease intractable and more severe with the
progress of irreversible airway lesions. Therefore, an
emphasis is placed on the need of treatment aiming for
the control of airway inflammation early after the onset
of asthma. In particular, the possibility has been sug-
gested that early intervention with inhaled steroids may
achieve not only early control of symptoms with an
improvement of patients’ quality of life (QOL), but also
for the inhibition of airway remodeling. However, it still
seems difficult to say that sufficient evidence for such a
need of early intervention is established in pediatric
asthma, even though the clinical usefulness and safety of
inhaled steroids have been proven in children. In the
present review, we summarize the current issues and
possibilities of early intervention with inhaled steroids in
childhood asthma by referring to our own data and
present the points that should be investigated further in
the future.
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It is confirmed that the prevalence of pediatric asthma
has been increasing in recent years.
 
1
 
 Approximately 20%
of adult asthma patients are those who have continu-
ously suffered from asthma from childhood or those who
have recurrence after temporary relief of childhood
asthma. In consideration of these epidemiological data,
it is expected that appropriate early intervention for
asthma soon after onset in childhood may alleviate
symptoms, normalize respiratory function and eventually
increase the spontaneous remission rate of pediatric
asthma.
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We have investigated the long-term prognosis of
severe intractable pediatric asthma and found that many
patients at puberty or during adolescence still manifest
mild symptoms and obstructive changes in respiratory
function tests even though the asthma itself has become
milder.
 
2
 
 We also investigated the effects of inhaled
beclomethasone dipropionate (BDP) in adolescent asth-
matic out-patients who still showed obstructive changes
in respiratory function although their asthma symptoms
were relieved after treatment with inhaled disodium
cromoglycate (DSCG). That study confirmed that BDP
achieved further relief of symptoms and significant
improvement of respiratory function (M Kameda 
 
et al.
 
,
unpubl. data, 1993). However, few patients demon-
strated complete normalization of respiratory function
and many patients were still suggested to have peripheral
airway narrowing (Fig. 1). It is inferred that continuous
treatment focusing only on the symptoms does not
sufficiently inhibit airway inflammation, which results in
progression of remodeling and, eventually, fails to
achieve normalization of respiratory function.
Agertoft 
 
et al
 
.
 
3
 
 investigated the relationship between
time from diagnosis of asthma to start of inhaled steroid
therapy and the rate of improvement of lung function
in asthmatic children. They stressed the need for early
intervention with inhaled steroids, suggesting a possibility
that failure to use inhaled steroids soon after diagnosis
may result in inhibition of normal development of lung
function. This is consistent with reports proving the useful-
ness of early intervention with inhaled steroids in adult
asthma.
 
4,5
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We previously investigated the need and effectiveness
of holistic asthma therapy by regarding asthma as a
disease with multiple factors and reported that preven-
tive drug therapy is unnecessary in most cases of mild
asthma in children.
 
6
 
 Nevertheless, because airway
inflammation is shown to exist even in mild asthma,
the influence of airway inflammation on the long-term
prognosis should be investigated carefully. Therefore,
we evaluated the usefulness of early intervention with
BDP and DSCG in children with intermittent or mild
persistent asthma aged 3–12 years who had recurrent
episodes of relatively mild asthma symptoms soon after
the first diagnosis (T Inoue 
 
et al.
 
, unpubl. data, 2000).
After a 1 month run-in period, the patients whose
guardians consented to the treatment method were
 
Fig. 1
 
Effect of beclomethasone dipropionate (BDP) on respiratory function in mild asthmatics with chronic air flow limitation
(
 
n
 
 = 17 cases (11 male, six female); mean age 12.1 
 
±
 
 2.8 years (range 9–17 years)). The dose of BDP administered was
11.3 
 
±
 
 4.9 
 
µ
 
g/kg per day (range 300–600 
 
µ
 
g/kg daily). *
 
P
 
 < 0.01 (paired 
 
t
 
-test). FEV
 
1
 
, forced expiratory volume in 1 s; V
 
·
 
50
 
,
expiratory flow at 50% of the forced vital capacity.
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randomized to a non-treatment group without any
preventive drug therapy, a DSCG group receiving one
ampoule (20 mg) of DSCG inhalation solution twice
daily via nebulization or a BDP group receiving BDP
200 
 
µ
 
g twice daily using an large volume spacer. The
clinical courses of the patients were followed at regular
visits and by asthma diary cards (including peak flow
monitoring at home). Lifestyle guidance, such as
improvement of living conditions, was given to all
patients whenever necessary. According to asthma
symptoms, bronchodilators were concomitantly used as
needed or for a short period of time. As shown in
Table 1, the number of patients who regularly visited the
hospital over 1 year and maintained good compliance
was 10 (55.6%), 14 (60.9%) and eight (42.1%) in the
non-treatment, DSCG and BDP groups, respectively. In
the non-treatment group, many patients stopped visiting
the hospital, highlighting the difficulty in managing
patients with mild asthma over a long period of time. In
the BDP group, there were many cases whose guardians
did not give consent and preferred another treatment.
This suggests that asthmatic patients and their guardians
in Japan are still very cautious about the use of inhaled
steroids. In comparison with the symptom scores during
the 1 month prior to treatment and over almost the same
period after 1 year, no significant change was seen from
pre- to post-dose mean scores in the non-treatment
group. However, the standard deviation became larger
after treatment, indicating that there were both patients
with an improvement of asthma symptoms and patients
with worsening of asthma symptoms. In contrast, signifi-
cant improvement in the symptom score was observed in
the DSCG and BDP groups. There was no difference in
the magnitude of improvement between these two
groups (Fig. 2). No symptoms or abnormal laboratory
data suggestive of adverse drug reactions were reported
in any of the groups. The results demonstrate that
introduction of anti-inflammatory inhaled drug therapy
in patients with mild asthma early after the onset of
asthma can alleviate the symptoms of asthma, but the
data did not show that aggressive introduction of BDP is
superior to inhalation of DSCG. Further investigations
are required to determine the effect on the long-term
prognosis. It has also become clear that many aspects
remain to be investigated in the future, such as the
inclusion criteria of target patients, the types and doses
of drugs, treatment period, methods to ensure treatment
or inhalation compliance and adverse drug reactions.
König and Shaffer
 
7
 
 retrospectively reviewed the results
of step-wise therapy for each severity of asthma recom-
mended by the International Pediatric Asthma Treatment
Guideline announced in 1989.
 
8
 
 König and Shaffer
 
7
 
 con-
cluded that it is valuable to start treatment with DSCG in
patients with mild asthma earlier than the timing men-
tioned in the guidelines, but the usefulness of the early
introduction of inhaled steroids was not established.
In a report investigating the usefulness of the long-
term use of inhaled steroids in mild to moderate pediatric
asthma,
 
9,10
 
 statistical superiority was demonstrated in the
population treated with inhaled steroids, but the efficacy
gain was small. Further investigations are required to
determine whether the early introduction of inhaled
steroids should be positively recommended in actual
clinical practice.
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It has been pointed out that approximately 80% of
asthmatic children had the first onset of asthma by the
age of 3 years and that the age at first onset of
asthma has decreased in recent years.
 
1
 
 For consider-
ation of early intervention in children, correct diag-
nosis of asthma shortly after onset is essential in infancy
 
Table 1
 
Status of treatment compliance in the early intervention trial (T Inoue 
 
et al.
 
, unpubl. data, 2000)
Treatment 
None DSCG BDP
1 year observation 10 (55.6) 14 (60.9) 8 (42.1)
Change of treatment 1 (5.6) 5 (21.7) 1 (5.3)
Change of hospital – 2 (8.7) –
Discontinuation of hospital visits 7 (38.9) 2 (8.7) 3 (15.8)
Refusal of treatment – – 7 (36.8)
Total 18 (100) 23 (100) 19 (100)
 
Data show the number of patients in each group, with percentages given in parentheses.
DSCG, disodium cromoglycate; BDP, beclomethasone dipropionate.
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Fig. 2
 
Clinical effects of anti-inflammatory drugs in an early intervention trial (T Inoue 
 
et al.
 
, unpubl. data, 2000). The symptom
score is expressed as a monthly sum of daily scores (severe attack = 9, moderate attack = 6, mild attack = 3, wheezing = 1,
cough = 0.5). DSCG, disodium cromoglycate; BDP, beclomethasone dipropionate.
 
Table 2
 
Results of long-term inhaled steroid therapy for young asthmatic children
At start 5 years later
Change in asthma severity (
 
n
 
)
Severe 10 1
Moderate 6 1
Mild 0 9
No attack 0 5
Change in beclomethasone dipropionate dose (
 
µ
 
g/day; 
 
n
 
)
600 11 2
400 5 8
300 0 2
200 0 2
None 0 2
Change in the use of concomitant drugs (
 
n
 
)
DSCG + salbutamol 15 8
Slow-release theophylline 16 11
Oral steroid 3 1
None 0 5
Adverse reactions (
 
n
 
)
Oral candidiasis 3
Hoarseness 1
Change in height
SD score 0.397 0.076
Respiratory function
%FEV
 
1
 
100.0
%V·
 
50
 
92.2
 
Prognosis was investigated in 16 children with asthma younger than 6 years of age (mean age 38.9 months) who started beclomethasone
dipropionate (BDP) treatment during the period 1990–1992.
DSCG, disodium cromoglycate; FEV
 
1
 
, forced expiratory volume in 1 s; V
 
·
 
50
 
, expiratory flow at 50% of the forced vital capacity.
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and early childhood. However, infants and very young
children are likely to present with wheezing and dyspnea
owing to their anatomical and physiological character-
istics. Martinez 
 
et al
 
.
 
11
 
 performed a prospective cohort
study and reported that more than half the patients
having wheezing by the age of 3 years outgrew the
symptoms by the age of 6 years. They pointed out
the difficulty in differentiating transient manifestation of
wheezing and typical asthma because of the clinical
characteristics of small children.
 
12
 
 When the cell compo-
nents of airway secretions from wheezing children were
analyzed, an increased number of eosinophils and mast
cells involved in allergic inflammation was found in
some children, but not in others.
 
13
 
 In a long-term
investigation of respiratory function in wheezing chil-
dren,
 
14,15
 
 patients with severe asthma exhibited persist-
ently low values from the start of the observation period,
whereas the values in patients with mild asthma were not
low but similar to those in healthy children. Because
these patients were not treated with inhaled steroids, the
results have cast doubt over the value of early inter-
vention with inhaled steroids in cases of mild asthma.
Studying the clinical efficacy of inhaled steroids in
infants and very young children can be paraphrased as
studying the usefulness of early intervention with inhaled
steroids in asthmatic infants and very young children.
Randomized double-blind clinical studies have already
confirmed clinically significant effects of inhaled steroids,
such as an improvement of symptoms and a reduction of
the use of reliever medications.
 
16–18
 
 In contrast, it has
been reported that there exist infants and very young
children whose asthma cannot be completely controlled
with inhaled steroids and that the efficacy of inhaled
steroids is poor in mild asthmatic children who have
recurrent episodes of wheezing caused by viral infections
with few allergic factors.
 
19,20
 
We studied the prognosis of 5 years treatment with
inhaled BDP at 600–800 
 
µ
 
g/day given with a large
volume spacer in severe asthmatic patients younger than
6 years of age (mean age 38.9 months) whose asthma
symptoms were not well controlled by the concomitant
use of theophylline round the clock (RTC) and regular
nebulization of DSCG and salbutamol (M Kameda 
 
et al.
 
,
unpubl. data, 1998). As summarized in Table 2, the
severity of asthma became milder and the use of both
BDP and concomitant drugs decreased. Oral candidiasis
and hoarseness were reported transiently in three and
one patient, respectively, as possible adverse reactions
with BDP, but these events were resolved by symptomatic
treatment. No growth inhibition was observed. Although
respiratory function could not be measured before BDP
treatment, respiratory function data after 5 years treat-
ment were close to the predictive values. Hence, it is
judged that appropriate inhaled steroid therapy can
control asthma symptoms in infants and very young chil-
dren without lowering respiratory function or inhibiting
normal growth, even if the treatment is started after the
asthma becomes severe.
It is difficult to use simple objective variables, such as
lung function tests, in infants and very young children and
the asthma control has to depend on the clinical symp-
toms. Therefore, disease conditions in infants and very
young children should be very carefully determined. We
have obtained data showing that early intervention with
inhaled steroids may be effective not only for the control
of asthma symptoms, but also for the inhibition of sensiti-
zation by inhaled allergens. We retrospectively investi-
gated the sensitization status by mite allergens 1 year
after the start of BDP or DSCG inhalation in asthmatic
children aged 2 years or younger who had not been
sensitized by mite allergen (N Murayama 
 
et al.
 
, unpubl.
data, 2000). Although the BDP inhalation group (13
patients) seemed to have stronger atopic predispositions
than the DSCG inhalation group (22 patients), specific
IgE antibody to mite allergens was found to be positive in
one patient given BDP inhalation and in five patients
given DSCG inhalation. The study was a retrospective
study for only 1 year, so the results were inconclusive.
However, the results of the study suggest the possibility
that early intervention with inhaled steroids may inhibit
the establishment of sensitization by inhaled allergens.
This point is thought to be an interesting topic that should
be investigated further in the future.
CONCLUSIONS
With regard to early intervention with inhaled steroids in
childhood asthma, evidence suggesting the usefulness of
early intervention exists in school-age or older children,
so that this population can be regarded in the same
manner as the adult population. However, it cannot be
denied that the disease concept and the diagnosis of
asthma, as well as the clinical usefulness of and adverse
reactions to inhaled steroids, have not been investigated
sufficiently in infants and very young children. Future
investigations from various viewpoints are required to
determine the value of early intervention with inhaled
steroids in asthmatic infants and very young children.
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